Rho GTPases and Neuroprotection Model in Cancer Therapy
Rho GTPases and Neuroprotection Model in Cancer Therapy
批准号:
8232481
负责人:
QUN LU
金额:
$42.16万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-05-15 至 2016-04-30
关键词:
ActinsActivation AnalysisAntineoplastic AgentsCD95 AntigensCREB1 geneCisplatinClinicalCoupledCytoskeletonDose-LimitingDrug Delivery SystemsExhibitsFOS geneFamilyGene ExpressionGenetic TranscriptionImmunocompetentImmunohistochemistryIn VitroLaboratoriesLewis Lung CarcinomaMalignant Epithelial CellMalignant NeoplasmsMalignant neoplasm of lungMeasurementMeasuresMediatingModelingMolecularMusNerve DegenerationNeural ConductionNeuronsPathway interactionsPatientsPeripheral Nervous System DiseasesPharmaceutical PreparationsPhysiologicalPlatinumProtein FamilyQuality of lifeRecoveryRegimenResearchRho-associated kinaseSensorySerum Response FactorSignal PathwaySignal TransductionSmall Interfering RNATNFRSF6 geneTestingTherapeuticTouch sensationToxic effectUniversitiesbasecancer cellcancer therapycell motilitychemotherapycytotoxicityezringraduate studentimprovedin vivoinhibitor/antagonistinnovationkinase inhibitorlung Carcinomamoesinmouse modelneuroprotectionneurotoxicitynovelpreclinical studyprotein activationradixin proteinrelating to nervous systemresponserhorho GTP-Binding Proteinssmall moleculesural nervetumorundergraduate student
中文摘要
描述(申请人提供):广泛使用的化疗药物,如铂,表现出高水平的与治疗相关的毒性,包括神经毒性,通常是剂量限制的,可能在治疗结束后很长一段时间内对患者的生活质量造成毁灭性影响。我们已经证实p160ROCK/Rho激酶抑制剂Y-27632抑制RhoA信号,从而抑制癌细胞的运动和侵袭,可以逆转本实验室建立的新型顺铂诱导的周围神经病小鼠模型中抗癌药物诱导的神经变性。很少有分子通路显示出这种独特的抑制癌细胞扩张的能力,同时显示出神经保护作用。由于铂和Y-27632都已被证明在临床上是安全的,并可以扩展到许多抗癌药物应用,因此建立这一途径的潜在机制以提高抗癌疗效将具有重大影响。在这个R15区域项目中,我们建议使用正常和携带肿瘤的小鼠来验证这样的假设,即抑制Rho GTPase信号与化疗药物一起提供了一种在保护神经元的同时攻击癌症的有效策略。目的1研究抑制Rho GTPase信号通路对顺铂诱导的神经毒性的保护作用的两种可能的分子机制(ERM蛋白激活和重新分布到肌动蛋白激活Fas受体/CD95和SRF依赖的基因转录)。特定目的2将应用创新的小分子rac1/Cdc42激活剂/抑制剂库来研究Rho GTP酶亚类之间的串扰是否增强了RhoA抑制介导的对CIPN的抑制。具体目的3将研究在顺铂抗癌治疗中对RhoA通路的抑制和对小鼠肺癌转移模型的神经保护作用。我们将确定顺铂和Y-27632(或RhoA/SRF依赖的转录抑制物CCG-1423)组合是否在降低免疫活性小鼠接种同基因Lewis肺癌细胞的CIPN(通过改善腓肠神经传导和触觉)的同时增强抗癌效果。这些研究将使Rho GTPase信号转导系统成为临床癌症治疗中神经保护和癌症抑制相结合的创新药物靶点。
公共卫生相关性:广泛使用的化疗药物,如铂,表现出高水平的与治疗相关的毒性,包括神经毒性,这种毒性通常是剂量有限的,可能在治疗结束后很长一段时间内对患者的生活质量造成毁灭性影响。该项目是一项临床前研究,旨在确定抑制Rho GTPase信号与化疗药物联合使用是否提供了一种在保护神经元的同时攻击癌症的有效策略。
英文摘要
DESCRIPTION (provided by applicant): Widely-used chemotherapy drugs, such as platinum, exhibit a high level of treatment-associated toxicity including neurotoxicity which is often dose limiting and can be devastating to a patient's quality of life long after the therapy ends. We have identified that suppression of RhoA signaling by p160ROCK/Rho kinase inhibitor Y-27632, which inhibits cancer cell motility and invasion, can reverse anti-cancer drug-induced neurodegeneration in the novel cisplatin-induced peripheral neuropathy (CIPN) mouse model developed in this laboratory. Few molecular pathways demonstrate this unique capacity of inhibiting cancer cell expansion while exhibiting neuroprotective effects. Establishing the mechanisms underlying this pathway to increase cancer-attacking efficacy will have significant impact since both platinum and Y-27632 have proven to be clinically safe and can expand to many anti-cancer drug applications. In this R15 AREA project, we propose to use both normal and tumor-bearing mice to test the hypothesis that suppression of Rho GTPase signaling coupled with chemotherapy drugs provides an effective strategy for attacking cancer while protecting neurons. Specific aim 1 will investigate two potential molecular mechanisms (ERM protein activation and redistribution to actin to activate Fas receptor/CD95 and SRF-dependent gene transcription) by which suppression of Rho GTPase signaling pathway protects neurons from cisplatin-induced neurotoxicity. Specific aim 2 will apply innovative small molecule Rac1/Cdc42 activator/inhibitor reservoirs to investigate whether crosstalks among the subclasses of Rho GTPases enhance the RhoA suppression-mediated inhibition of CIPN. Specific aim 3 will investigate RhoA pathway inhibition and neuroprotection in cisplatin anti-cancer therapy in murine models of primary and metastatic lung carcinoma. We will determine whether cisplatin and Y-27632 (or RhoA/SRF-dependent transcription inhibitor CCG-1423) combinations enhance anti-cancer efficacy while reducing CIPN (measured by improving sural nerve conduction and touch sensation) in immunocompetent mice inoculated with syngeneic Lewis Lung carcinoma cells. These studies, engaging the continuous graduate and undergraduate student research in this laboratory, will establish Rho GTPase signaling as an innovative drug target for combined neuroprotection and cancer inhibition in clinical cancer therapy.
PUBLIC HEALTH RELEVANCE: Widely-used chemotherapy drugs, such as platinum, exhibit a high level of treatment-associated toxicity including neurotoxicity which is often dose limiting and can be devastating to a patient's quality of life long after the therapy ends. This project is a preclinical study to determine whether suppression of Rho GTPase signaling coupled with chemotherapy drugs provides an effective strategy for attacking cancer while protecting neurons.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Homeostatic Reset as a New Therapeutic Paradigm for Slow Progression Diseases
-
批准号:10273546
-
项目类别:
-
资助金额:$62.71万
-
财政年份:2021
-
负责人:QUN LU
-
依托单位:
Homeostatic Reset as a New Therapeutic Paradigm for Slow Progression Diseases
-
批准号:10689335
-
项目类别:
-
资助金额:$31.5万
-
财政年份:2021
-
负责人:QUN LU
-
依托单位:
Homeostatic Reset as a New Therapeutic Paradigm for Slow Progression Diseases
-
批准号:10796004
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:QUN LU
-
依托单位:
Homeostatic Reset as a New Therapeutic Paradigm for Slow Progression Diseases
-
批准号:10488273
-
项目类别:
-
资助金额:$61.44万
-
财政年份:2021
-
负责人:QUN LU
-
依托单位:
Rho GTPases and Neuroprotection Model in Cancer Therapy
-
批准号:8769217
-
项目类别:
-
资助金额:$7.84万
-
财政年份:2012
-
负责人:QUN LU
-
依托单位:
delta-Catenin and Cell-Cell Adhesion in Prostate Cancer
-
批准号:7035153
-
项目类别:
-
资助金额:$18.95万
-
财政年份:2006
-
负责人:QUN LU
-
依托单位:
delta-Catenin and Cell-Cell Adhesion in Prostate Cancer
-
批准号:7186628
-
项目类别:
-
资助金额:$18.4万
-
财政年份:2006
-
负责人:QUN LU
-
依托单位:
delta-Catenin and Cell-Cell Adhesion in Prostate Cancer
-
批准号:8068992
-
项目类别:
-
资助金额:$1.72万
-
财政年份:2006
-
负责人:QUN LU
-
依托单位:
delta-Catenin and Cell-Cell Adhesion in Prostate Cancer
-
批准号:7554661
-
项目类别:
-
资助金额:$18.4万
-
财政年份:2006
-
负责人:QUN LU
-
依托单位:
delta-Catenin and Cell-Cell Adhesion in Prostate Cancer
-
批准号:7345429
-
项目类别:
-
资助金额:$18.4万
-
财政年份:2006
-
负责人:QUN LU
-
依托单位:
Delta-Catenin Cleavage by Presenilin and Synaptic Remodeling
-
批准号:6959771
-
项目类别:
-
资助金额:$6.06万
-
财政年份:2005
-
负责人:QUN LU
-
依托单位:
Delta-Catenin Cleavage by Presenilin and Synaptic Remodeling
-
批准号:7095974
-
项目类别:
-
资助金额:$5.91万
-
财政年份:2005
-
负责人:QUN LU
-
依托单位:
海外基金